Issuer directory · Biotechnology · page 8
Biotechnology: issuers 701 to 800 of 830.
Ranked by the amount reported sold on the newest Form D. Page 1 holds the largest raises in the group.
| Issuer | Reported sold | Investors | Exemption | Newest notice | Filings | Platform |
|---|---|---|---|---|---|---|
| Biomark Diagnostics Inc. | $2.5M | 10 | 506(b) | Apr 14, 2025 | 1 | direct |
| BirchBioMed Inc. | $2.5M | 18 | 506(b) | Oct 1, 2025 | 2 | direct |
| Embold Therapeutics, Inc. | $2.5M | 7 | 506(b) | Jul 24, 2026 | 2 | direct |
| Commense Bio, Inc. | $2.5M | 31 | 506(b) | Jun 12, 2026 | 1 | direct |
| Cadenza Bio, Inc. | $2.4M | 10 | 506(b) | Aug 28, 2025 | 1 | direct |
| Moonlight Therapeutics Inc. | $2.4M | 30 | 506(b) | Aug 16, 2024 | 1 | direct |
| Clearmind Medicine Inc. | $2.4M | 12 | 506(b) | Feb 7, 2024 | 1 | direct |
| Capsulomics, Inc. | $2.4M | 10 | 506(b) | Mar 19, 2025 | 2 | direct |
| iXpressGenes, Inc. | $2.4M | 13 | 506(b) | Jun 26, 2025 | 1 | direct |
| Orgenesis Inc. | $2.3M | 46 | 506(b) | Mar 14, 2024 | 1 | direct |
| Origin Endoscopy Inc. | $2.3M | 5 | 506(b) | Jun 10, 2025 | 3 | direct |
| Canal Biosciences, Inc. | $2.3M | 18 | 506(b) | Apr 13, 2026 | 1 | direct |
| CARI Health, Inc. | $2.3M | 11 | 506(b) | Feb 14, 2024 | 1 | direct |
| TellBio, Inc. | $2.3M | 23 | 506(b) | Mar 29, 2023 | 1 | direct |
| Aegle Therapeutics Corp | $2.3M | 17 | 506(b) | Aug 28, 2026 | 1 | direct |
| Keliomics, Inc. | $2.3M | 17 | 506(b) | Nov 30, 2023 | 2 | direct |
| KALA BIO, Inc. | $2.3M | 20 | 506(b) | Feb 13, 2026 | 1 | direct |
| Tinos Therapeutics, Inc. | $2.3M | 3 | 506(b) | Apr 17, 2026 | 2 | direct |
| ENRICH BIOSYSTEMS INC. | $2.2M | 17 | 506(b) | May 20, 2024 | 1 | direct |
| TuHURA Biosciences, Inc./NV | $2.2M | 36 | 506(b) | Jun 13, 2025 | 1 | direct |
| Pneumeric, Inc. | $2.2M | 23 | 506(b) | Jul 25, 2023 | 3 | direct |
| Circula-AI Inc | $2.2M | 11 | 506(b) | Mar 13, 2025 | 1 | direct |
| Voxcell BioInnovation Inc. | $2.2M | 31 | 506(b) | Sep 1, 2026 | 1 | direct |
| TPEG NANO QP INVESTORS LLC | $2.2M | 41 | 506(b) | Nov 30, 2023 | 1 | direct |
| Exin Therapeutics, Inc. | $2.2M | 28 | 506(b) | Feb 10, 2026 | 1 | direct |
| RCE Technologies, Inc. | $2.1M | 37 | 506(b) | Nov 20, 2025 | 7 | direct |
| Starton Therapeutics Inc. | $2.1M | 16 | 506(b) | Oct 22, 2024 | 1 | direct |
| Better Therapeutics, Inc. | $2.1M | 10 | 506(b) | Aug 11, 2023 | 1 | direct |
| Angiocrine Bioscience, Inc. | $2.1M | 16 | 506(b) | Sep 5, 2025 | 1 | direct |
| Contamination Source Identification Inc. | $2.1M | 16 | 506(b) | Apr 9, 2026 | 4 | direct |
| Willow Neuroscience, Inc. | $2.1M | 19 | 506(b) | Jul 10, 2023 | 2 | direct |
| NovaDerm Aid Fund Ni LLC | $2.0M | 24 | 506(c) | Apr 17, 2023 | 1 | direct |
| RNAV8 BIO, INC. | $2.0M | 42 | 506(b) | Mar 17, 2025 | 4 | direct |
| NovaDerm Aid Fund Zeta LLC | $2.0M | 19 | 506(c) | Apr 17, 2023 | 1 | direct |
| NovaDerm Aid Fund Gamma, L.L.C. | $2.0M | 10 | 506(c) | Apr 17, 2023 | 1 | direct |
| Intus Biosciences, LLC | $2.0M | 25 | 506(b) | Jul 16, 2024 | 1 | direct |
| Elastrin Therapeutics, Inc. | $2.0M | 2 | 506(b) | Nov 3, 2023 | 2 | direct |
| NovaDerm Aid Fund X L.L.C. | $2.0M | 18 | 506(b) | Apr 17, 2023 | 1 | direct |
| NovaDerm Aid Fund I, L.L.C. | $2.0M | 12 | 506(b) | Apr 17, 2023 | 1 | direct |
| NovaDerm Aid Fund Eta LLC | $2.0M | 18 | 506(c) | Apr 17, 2023 | 1 | direct |
| NovaDerm Aid Fund VII L.L.C. | $2.0M | 21 | 506(b) | Apr 17, 2023 | 1 | direct |
| NovaDerm Aid Fund Iota LLC | $2.0M | 14 | 506(c) | Apr 17, 2023 | 1 | direct |
| NovaDerm Aid Fund Beta, L.L.C. | $2.0M | 16 | 506(c) | Apr 17, 2023 | 1 | direct |
| NovaDerm Aid Fund Theta LLC | $2.0M | 13 | 506(c) | Apr 17, 2023 | 1 | direct |
| NovaDerm Aid Fund Mi LLC | $2.0M | 11 | 506(c) | Apr 17, 2023 | 1 | direct |
| Healix Clinical Laboratory LLC | $2.0M | 11 | 506(b) | Jul 5, 2023 | 1 | direct |
| NovaDerm Aid Fund XI L.L.C. | $2.0M | 19 | 506(b) | Apr 17, 2023 | 1 | direct |
| NovaDerm Aid Fund VI L.L.C. | $2.0M | 18 | 506(b) | Apr 17, 2023 | 1 | direct |
| NovaDerm Aid Fund II, L.L.C. | $2.0M | 20 | 506(b) | Apr 17, 2023 | 1 | direct |
| NovaDerm Aid Fund V, L.L.C. | $2.0M | 22 | 506(b) | Apr 17, 2023 | 1 | direct |
| RLL, LLC | $2.0M | 11 | 506(b) | Apr 6, 2026 | 1 | direct |
| Gut-Brain-Axis Therapeutics Inc. | $2.0M | 22 | 506(c) | Oct 27, 2026 | 2 | direct |
| Sethera Therapeutics, Inc | $1.9M | 21 | 506(b) | Oct 30, 2024 | 1 | direct |
| SalivIQ Diagnostics Inc. | $1.9M | 50 | 506(b) | Sep 23, 2026 | 2 | direct |
| GelMEDIX, Inc. | $1.9M | 17 | 506(b) | Mar 26, 2024 | 1 | direct |
| XDemics Corp | $1.9M | 1 | 506(b) | Sep 13, 2024 | 3 | direct |
| Hillhurst Biopharmaceuticals, Inc. | $1.8M | 10 | 506(b) | Sep 26, 2023 | 1 | direct |
| Alixia, Inc. | $1.8M | 19 | 506(b) | Jul 23, 2024 | 1 | direct |
| BioLattice Ophthalmics, Inc, | $1.8M | 7 | 506(b) | Oct 28, 2026 | 2 | direct |
| Argonaute RNA Ltd | $1.8M | 27 | 506(b) | Sep 24, 2026 | 1 | direct |
| EOLO USA, Inc. | $1.8M | 9 | 506(b) | Feb 14, 2023 | 2 | direct |
| Protein Dynamic Solutions, Inc. | $1.8M | 10 | 506(b) | Nov 7, 2025 | 1 | direct |
| InGeneron, Inc. | $1.7M | 10 | 506(b) | Mar 4, 2024 | 1 | direct |
| Mitera Biosciences Inc. | $1.7M | 6 | 506(b) | Dec 22, 2025 | 2 | direct |
| Vitazi.AI, Inc. | $1.7M | 7 | 506(b) | Dec 27, 2023 | 2 | direct |
| Tetrous, Inc. | $1.7M | 64 | 506(b) | Apr 22, 2026 | 1 | direct |
| Grid Therapeutics LLC | $1.7M | 11 | 506(b) | Jan 5, 2023 | 1 | direct |
| Hera Biotech, Inc. | $1.7M | 26 | 506(b) | Sep 23, 2026 | 2 | direct |
| ORF Biologics, Inc. | $1.7M | 17 | 506(b) | Jul 31, 2026 | 1 | direct |
| Lindy Biosciences, Inc. | $1.7M | 10 | 506(b) | Mar 19, 2024 | 1 | direct |
| Therapeutic Neuromodulation Systems LLC | $1.7M | 29 | 506(b) | Sep 21, 2026 | 1 | direct |
| Bio Usawa Inc. | $1.7M | 25 | 506(b) | Dec 17, 2025 | 1 | direct |
| FluidForm Bio, Inc. | $1.7M | 20 | 506(b) | Aug 27, 2026 | 1 | direct |
| PathCision Medicine, Inc. | $1.7M | 8 | 506(b) | Feb 5, 2026 | 2 | direct |
| Ascoltare Holdings LLC | $1.7M | 10 | 506(b) | Oct 23, 2026 | 1 | direct |
| VST Operating Corp. | $1.7M | 29 | 506(c) | May 15, 2026 | 1 | direct |
| VQ Biomedical, Inc. | $1.6M | 21 | 506(b) | Mar 27, 2025 | 1 | direct |
| Kaida BioPharma Inc. | $1.6M | 44 | 506(b) | Sep 1, 2026 | 2 | direct |
| Patensee, Inc. | $1.6M | 10 | 506(b) | Feb 20, 2025 | 1 | direct |
| PANGIA BIOTECH, INC. | $1.6M | 18 | 506(c) | May 11, 2026 | 1 | direct |
| Oro Muscles, Inc. | $1.6M | 18 | 506(b) | Jun 18, 2025 | 1 | direct |
| Dev4 LLC | $1.5M | 27 | 506(b) | Sep 5, 2025 | 1 | direct |
| Anchor Balloon, Inc. | $1.5M | 36 | 506(b) | Apr 4, 2024 | 1 | direct |
| Inherent Biosciences, Inc. | $1.5M | 12 | 506(b) | May 31, 2023 | 1 | direct |
| ProEncia Biotechnology Inc. | $1.5M | 14 | 506(b) | Aug 26, 2026 | 1 | direct |
| Haku Bio, Inc. | $1.5M | 6 | 506(b) | Jun 10, 2026 | 2 | direct |
| C4 Imaging, LLC | $1.5M | 43 | 506(b) | Jul 16, 2024 | 2 | direct |
| Xeno Biosciences Inc. | $1.5M | 64 | 506(b) | Jan 5, 2023 | 1 | direct |
| TopoDx, Inc. | $1.5M | 10 | 506(b) | Sep 5, 2025 | 2 | direct |
| HumanImage Inc | $1.5M | 20 | 506(c) | Apr 8, 2026 | 1 | direct |
| ARC Medical Inc. | $1.5M | 10 | 506(b) | Nov 10, 2025 | 9 | direct |
| Akelos, Inc. | $1.5M | 81 | 506(c) | Mar 16, 2026 | 1 | direct |
| Astek Diagnostics, Inc. | $1.4M | 11 | 506(b) | Aug 28, 2023 | 3 | direct |
| BioRestorative Therapies, Inc. | $1.4M | 16 | 506(b) | Oct 9, 2025 | 1 | direct |
| Trinity Nuclein Rd III Investors LLC | $1.4M | 25 | 506(b) | Dec 18, 2023 | 2 | direct |
| RUSKID LLC | $1.4M | 16 | 506(b) | Feb 13, 2026 | 1 | direct |
| ACESIS HOLDINGS CORP. | $1.4M | 15 | 506(b) | Jun 9, 2023 | 4 | direct |
| CELESTIAL THERAPEUTICS INC. | $1.3M | 13 | 506(c) | Apr 11, 2024 | 22 | direct |
| PiroGon, Inc. | $1.3M | 25 | 506(b) | Mar 12, 2024 | 2 | direct |
| Jabez Biosciences, Inc. | $1.3M | 18 | 506(b) | Oct 21, 2025 | 1 | direct |